Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th
Investor conference call to be held at 8:15 am ET on Sept. 5th
LEIDEN, The Netherlands and CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company
dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases,
today announced it will issue data from a planned interim analysis in the ongoing Phase 1/2 clinical trial of QR-110 in patients
with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation (the PQ-110-001 trial) at the 18th International Symposium on Retinal Degeneration (RD2018), which is being held on
Sept. 3-8, 2018 in Killarney, Ireland.
| |
Presentation Details:
|
| Presentation title: |
|
Intravitreal Antisense Oligonucleotide Therapy (QR‐110) for the Treatment of
Leber Congenital Amaurosis due to Photoreceptor Cilium Defect in Subjects
with the CEP290 p.Cys998X Mutation |
| Presenter: |
|
Dr. Artur Cideciyan, Research Professor of Ophthalmology at the Scheie Eye
Institute,
University of Pennsylvania and investigator of the PQ-110-001 trial |
| Date and Time: |
|
Wednesday, Sept. 5, 2018 at 8:30 am GMT |
| Session Details: |
|
Platform Session V: Drug Therapy |
| |
|
|
Investor conference call
Management will also host a conference call for its investors to discuss the presented interim Phase 1/2 data on Wednesday,
Sept. 5, 2018 starting at 8:15 am ET. Details for the call will be included in a press release the same day and will be made
available in the “Investors” section of ProQR’s website (www.proqr.com) under “Events and Presentations”.
About PQ-110-001 trial
PQ-110-001 is an open-label trial that has been designed to enroll approximately six children (age 6 - 17 years) and six adults
(≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Patients are receiving four
intravitreal injections of QR-110 into one eye; once every three months. The trial is being conducted at three specialized centers
with significant expertise in genetic retinal disease: the University of Iowa, Iowa City, IA, US, the Scheie Eye Institute at the
University of Pennsylvania, Philadelphia, PA, US and the Ghent University Hospital, Ghent, Belgium.
The primary objectives of the trial are safety and tolerability. Secondary objectives include pharmacokinetics as well as
restoration/improvement of visual function and retinal structure through ophthalmic endpoints such as visual acuity, full field
stimulus testing (FST), optical coherence tomography (OCT), pupillary light reflex (PLR), mobility course and fixation stability.
Changes in quality of life in the trial subjects are also being evaluated.
About Leber’s Congenital Amaurosis 10
Leber’s congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children and consists of a
group of diseases of which LCA 10 is one of the more severe forms. LCA10 is caused by mutations in the CEP290 gene, of
which the p.Cys998X mutation is the most common. LCA10 leads to early loss of vision causing most people to lose their sight in the
first few years of life. To date, there are no treatments approved or other products in clinical development that treat the
underlying cause of the disease. Approximately 2,000 people in the Western world have LCA10 because of this mutation.
About QR-110
QR-110 is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of Leber’s
congenital amaurosis 10 due to the p.Cys998X mutation in the CEP290 gene. The p.Cys998X mutation is a substitution of one
nucleotide in the pre-mRNA that leads to aberrant splicing of the mRNA and non-functional CEP290 protein. QR-110 is designed to
restore wild-type CEP290 mRNA leading to the production of wild-type CEP290 protein by binding to the mutated location in the
pre-mRNA causing normal splicing of the pre-mRNA. QR-110 is intended to be administered through intravitreal injections in the eye
and has been granted orphan drug designation in the United States and the European Union and fast track status
by the FDA.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based
on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar
expressions. Such statements include those relating to the RD2018 presentation, QR-110 and the PQ-110-001 trial, as well as our
clinical development plans for and therapeutic potential of our product candidates. Forward-looking statements are based on
management's beliefs and assumptions and on information available to management only as of the date of this press release. Our
actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including,
without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission,
including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should
not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com
